Nifty
Sensex
:
:
22795.90
75311.06
-117.25 (-0.51%)
-424.90 (-0.56%)

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 524816 | NSE: NATCOPHARM

1328.00
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1283.00
  •  1335.00
  •  1277.20
  •  1283.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  772176
  •  10161.20
  •  1639.00
  •  778.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 14,288.49
  • 7.66
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 12,927.39
  • 1.19%
  • 1.96

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 49.62%
  • 1.60%
  • 23.34%
  • FII
  • DII
  • Others
  • 17.94%
  • 5.25%
  • 2.25%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.09
  • 15.86
  • 27.16

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 23.43
  • 24.62
  • 46.06

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 26.28
  • 24.68
  • 101.38

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.64
  • 26.15
  • 18.10

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.03
  • 3.31
  • 2.97

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.87
  • 18.83
  • 15.34

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
77.34
113.41
119.41
47.97
P/E Ratio
17.47
11.91
11.32
28.17
Revenue
3999
5069
5603
3739
EBITDA
1751
2522
2821
893
Net Income
1388
2006
2141
803
ROA
22.1
27.4
22.5
8.2
P/Bk Ratio
4.13
3.17
2.55
2.34
ROE
25.88
29.77
24.85
9.44
FCFF
912.9
1404.36
1745.18
1106.42
FCFF Yield
3.93
6.04
7.51
4.76

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
474.80
758.60
-37.41%
1,371.10
1,031.40
32.94%
1,362.60
1,140.50
19.47%
1,068.30
897.90
18.98%
Expenses
436.00
490.50
-11.11%
566.80
573.40
-1.15%
557.80
612.50
-8.93%
571.00
558.80
2.18%
EBITDA
38.80
268.10
-85.53%
804.30
458.00
75.61%
804.80
528.00
52.42%
497.30
339.10
46.65%
EBIDTM
8.17%
35.34%
58.66%
44.41%
59.06%
46.30%
46.55%
37.77%
Other Income
176.30
37.00
376.49%
63.80
29.40
117.01%
48.10
19.70
144.16%
42.00
29.00
44.83%
Interest
4.40
4.60
-4.35%
4.10
4.20
-2.38%
5.20
4.20
23.81%
6.20
2.70
129.63%
Depreciation
47.00
44.20
6.33%
45.80
43.60
5.05%
44.10
43.50
1.38%
55.50
41.00
35.37%
PBT
163.70
256.30
-36.13%
818.20
439.60
86.12%
803.60
500.00
60.72%
477.60
324.40
47.23%
Tax
31.30
43.60
-28.21%
141.70
70.60
100.71%
135.10
79.70
69.51%
91.30
48.60
87.86%
PAT
132.40
212.70
-37.75%
676.50
369.00
83.33%
668.50
420.30
59.05%
386.30
275.80
40.07%
PATM
27.89%
28.04%
49.34%
35.78%
49.06%
36.85%
36.16%
30.72%
EPS
7.43
11.88
-37.46%
37.84
20.61
83.60%
37.35
23.48
59.07%
21.58
15.11
42.82%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
4,276.80
3,998.80
2,707.10
1,944.80
2,052.10
1,915.00
2,094.50
2,184.80
2,020.20
1,141.30
825.28
Net Sales Growth
11.71%
47.72%
39.20%
-5.23%
7.16%
-8.57%
-4.13%
8.15%
77.01%
38.29%
 
Cost Of Goods Sold
583.20
667.90
583.20
528.40
483.70
354.40
332.70
411.10
599.10
341.10
242.37
Gross Profit
3,693.60
3,330.90
2,123.90
1,416.40
1,568.40
1,560.60
1,761.80
1,773.70
1,421.10
800.20
582.90
GP Margin
86.36%
83.30%
78.46%
72.83%
76.43%
81.49%
84.12%
81.18%
70.34%
70.11%
70.63%
Total Expenditure
2,131.60
2,247.40
1,795.40
1,681.30
1,448.30
1,332.40
1,299.70
1,256.40
1,336.80
868.70
611.90
Power & Fuel Cost
-
88.90
81.90
76.40
61.10
62.40
59.60
56.20
50.50
43.70
43.24
% Of Sales
-
2.22%
3.03%
3.93%
2.98%
3.26%
2.85%
2.57%
2.50%
3.83%
5.24%
Employee Cost
-
525.00
486.70
444.80
414.90
375.00
355.90
325.60
243.20
189.60
136.92
% Of Sales
-
13.13%
17.98%
22.87%
20.22%
19.58%
16.99%
14.90%
12.04%
16.61%
16.59%
Manufacturing Exp.
-
368.40
279.60
353.60
165.70
243.30
276.40
182.60
141.20
105.20
73.04
% Of Sales
-
9.21%
10.33%
18.18%
8.07%
12.70%
13.20%
8.36%
6.99%
9.22%
8.85%
General & Admin Exp.
-
313.00
208.80
152.80
242.90
132.60
126.40
105.50
88.10
73.40
63.66
% Of Sales
-
7.83%
7.71%
7.86%
11.84%
6.92%
6.03%
4.83%
4.36%
6.43%
7.71%
Selling & Distn. Exp.
-
153.00
96.10
43.70
34.40
98.10
90.00
136.90
143.20
91.60
37.36
% Of Sales
-
3.83%
3.55%
2.25%
1.68%
5.12%
4.30%
6.27%
7.09%
8.03%
4.53%
Miscellaneous Exp.
-
131.20
59.10
81.60
45.60
66.60
58.70
38.50
71.50
24.10
37.36
% Of Sales
-
3.28%
2.18%
4.20%
2.22%
3.48%
2.80%
1.76%
3.54%
2.11%
1.86%
EBITDA
2,145.20
1,751.40
911.70
263.50
603.80
582.60
794.80
928.40
683.40
272.60
213.38
EBITDA Margin
50.16%
43.80%
33.68%
13.55%
29.42%
30.42%
37.95%
42.49%
33.83%
23.89%
25.86%
Other Income
330.20
128.10
128.50
99.00
106.00
107.40
130.20
40.40
13.90
9.90
14.91
Interest
19.90
19.20
14.50
17.70
13.30
21.50
19.30
15.40
18.50
22.90
31.68
Depreciation
192.40
186.80
163.80
142.60
116.90
99.80
81.00
66.20
54.40
51.00
47.27
PBT
2,263.10
1,673.50
861.90
202.20
579.60
568.70
824.70
887.20
624.40
208.60
149.34
Tax
399.40
285.20
146.60
32.20
137.20
110.60
182.30
192.00
139.50
52.80
3.95
Tax Rate
17.65%
17.04%
17.01%
15.92%
23.67%
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
PAT
1,863.70
1,388.30
715.30
170.00
440.90
460.80
644.40
696.20
486.00
157.10
134.62
PAT before Minority Interest
1,865.10
1,388.30
715.30
170.00
442.40
458.10
642.40
695.20
484.90
155.80
130.27
Minority Interest
1.40
0.00
0.00
0.00
-1.50
2.70
2.00
1.00
1.10
1.30
4.35
PAT Margin
43.58%
34.72%
26.42%
8.74%
21.49%
24.06%
30.77%
31.87%
24.06%
13.77%
16.31%
PAT Growth
45.85%
94.09%
320.76%
-61.44%
-4.32%
-28.49%
-7.44%
43.25%
209.36%
16.70%
 
EPS
104.06
77.52
39.94
9.49
24.62
25.73
35.98
38.87
27.14
8.77
7.52

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
5,853.10
4,873.80
4,263.60
4,121.60
3,773.50
3,489.00
3,072.20
1,649.30
1,295.70
846.05
Share Capital
35.80
36.50
36.50
36.50
36.40
36.50
36.90
34.90
34.80
33.23
Total Reserves
5,817.30
4,837.30
4,223.70
4,067.60
3,713.60
3,421.70
3,011.40
1,599.00
1,251.20
812.82
Non-Current Liabilities
61.00
100.50
135.10
142.90
117.80
83.40
47.10
37.70
28.00
119.23
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
94.03
Unsecured Loans
0.00
0.00
0.00
0.00
0.90
0.00
0.00
0.00
0.00
2.99
Long Term Provisions
70.90
85.30
95.70
99.60
90.20
71.00
32.40
21.90
12.50
9.50
Current Liabilities
972.80
683.10
710.40
525.60
685.30
728.70
592.00
626.50
493.10
413.74
Trade Payables
235.50
263.80
161.80
146.20
255.40
217.00
269.10
262.70
275.60
125.30
Other Current Liabilities
238.90
227.30
126.70
99.50
95.90
109.80
133.40
127.10
114.20
118.56
Short Term Borrowings
363.20
165.00
404.00
265.80
315.00
386.30
173.20
221.60
98.40
168.54
Short Term Provisions
135.20
27.00
17.90
14.10
19.00
15.60
16.30
15.10
4.90
1.33
Total Liabilities
6,886.90
5,657.40
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
Net Block
2,490.80
2,426.90
2,311.80
2,023.20
1,584.40
1,227.20
1,018.60
833.00
710.10
709.97
Gross Block
3,603.20
3,375.10
3,126.90
2,702.10
2,148.70
1,694.50
1,407.60
1,158.70
983.30
939.98
Accumulated Depreciation
1,112.40
948.20
815.10
678.90
564.30
467.30
389.00
325.70
273.20
225.82
Non Current Assets
2,863.40
2,657.10
2,622.40
2,447.10
2,262.20
1,955.90
1,584.40
1,230.30
984.70
901.08
Capital Work in Progress
137.30
64.30
129.50
223.40
518.00
637.60
480.00
336.30
211.80
128.96
Non Current Investment
95.90
87.30
104.40
151.90
83.60
19.90
8.10
0.10
0.10
1.57
Long Term Loans & Adv.
112.70
78.30
72.00
44.30
72.00
62.80
75.40
60.40
62.10
57.03
Other Non Current Assets
26.70
0.30
4.70
4.30
4.20
8.40
2.30
0.50
0.60
3.54
Current Assets
4,023.50
3,000.30
2,486.70
2,344.80
2,325.60
2,347.20
2,130.70
1,087.30
837.00
482.97
Current Investments
443.50
305.00
203.70
151.80
28.70
148.70
68.40
32.10
22.10
0.12
Inventories
700.50
742.90
762.00
798.20
558.00
529.00
438.40
348.90
357.30
220.00
Sundry Debtors
1,188.90
856.10
620.60
412.90
551.30
506.20
637.50
475.20
261.60
192.43
Cash & Bank
952.90
546.30
206.10
283.50
66.00
279.50
183.70
35.80
45.20
13.36
Other Current Assets
737.70
64.40
88.10
94.70
1,121.60
883.80
802.70
195.30
150.80
57.06
Short Term Loans & Adv.
638.20
485.60
606.20
603.70
1,030.00
776.40
749.50
169.50
125.40
40.97
Net Current Assets
3,050.70
2,317.20
1,776.30
1,819.20
1,640.30
1,618.50
1,538.70
460.80
343.90
69.23
Total Assets
6,886.90
5,657.40
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
1,211.60
849.10
46.50
298.80
417.30
668.80
463.60
345.80
112.20
92.67
PBT
1,673.50
861.90
202.20
579.60
568.70
824.70
887.20
624.40
208.60
134.22
Adjustment
133.80
102.00
123.90
62.10
54.00
14.30
75.60
100.20
90.50
68.14
Changes in Working Capital
-309.40
62.70
-231.40
-212.90
-97.60
8.60
-294.60
-253.00
-140.70
-85.96
Cash after chg. in Working capital
1,497.90
1,026.60
94.70
428.80
525.10
847.60
668.20
471.60
158.40
116.41
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-286.30
-177.50
-48.20
-130.00
-107.80
-178.80
-204.60
-125.80
-46.20
-23.74
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,032.70
-477.10
-5.30
-103.30
-167.00
-612.20
-1,115.50
-299.40
-175.50
-114.75
Net Fixed Assets
-273.50
-113.40
-204.80
-250.20
-335.80
-436.10
-392.40
-299.40
-303.91
-100.13
Net Investments
-84.20
-107.50
-213.00
-145.90
53.30
-94.80
-54.80
-1.00
37.47
-42.37
Others
-675.00
-256.20
412.50
292.80
115.50
-81.30
-668.30
1.00
90.94
27.75
Cash from Financing Activity
-246.90
-363.00
34.80
-185.70
-250.80
-50.90
650.90
-47.70
154.00
29.07
Net Cash Inflow / Outflow
-68.00
9.00
76.00
9.80
-0.50
5.70
-1.00
-1.30
90.70
6.99
Opening Cash & Equivalents
131.90
111.10
25.80
19.80
28.30
21.70
23.50
24.20
-164.10
10.22
Closing Cash & Equivalent
70.40
131.90
111.10
25.80
19.80
28.30
21.70
23.50
-74.20
12.44

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
326.99
267.06
233.44
224.88
206.04
189.49
165.22
93.63
73.91
50.91
ROA
22.13%
13.29%
3.43%
9.43%
10.30%
16.02%
23.05%
23.43%
9.72%
10.10%
ROE
25.88%
15.66%
4.06%
11.27%
12.71%
19.75%
29.70%
33.21%
14.62%
16.57%
ROCE
30.08%
18.06%
4.86%
13.99%
14.82%
23.71%
35.28%
39.21%
18.04%
15.62%
Fixed Asset Turnover
1.24
0.89
0.76
0.86
1.07
1.47
1.72
1.93
1.23
0.95
Receivable days
86.16
93.53
85.10
84.44
93.77
91.36
92.22
65.12
70.27
67.76
Inventory Days
60.81
95.32
128.47
118.77
96.38
77.28
65.25
62.41
89.35
87.33
Payable days
136.43
133.18
106.38
151.52
65.96
72.53
81.42
78.30
85.42
73.36
Cash Conversion Cycle
10.54
55.67
107.20
51.68
124.19
96.11
76.05
49.23
74.21
81.73
Total Debt/Equity
0.06
0.03
0.09
0.06
0.08
0.11
0.06
0.14
0.09
0.37
Interest Cover
88.16
60.44
12.42
44.58
27.45
43.73
58.61
34.75
10.11
5.24

News Update:


  • Natco Pharma receives approval for ANDA for Bosentan tablets
    10th Feb 2025, 11:30 AM

    It has sole First-to-File status for the product and is eligible for a 180-day exclusivity at the time of launch

    Read More
  • Natco Pharma gets ANDA approval for Everolimus tablets for oral suspension
    30th Jan 2025, 09:59 AM

    NATCO’s marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc plans to launch the product immediately in the US market

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.